Showing 3,221 - 3,240 results of 21,342 for search '(( significant decrease decrease ) OR ( significantly delayed decrease ))', query time: 0.46s Refine Results
  1. 3221
  2. 3222
  3. 3223

    Changes in the neutrophil count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
  4. 3224

    Changes in the platelet count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
  5. 3225

    Changes in the white blood cell count. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
  6. 3226

    Changes in the hemoglobin. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
  7. 3227

    WBC and ANC on day 7 post-chemotherapy. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
  8. 3228

    General clinical data of 88 patients with NPC. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
  9. 3229

    CONSORT participant flow diagram. by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
  10. 3230

    S4 File - by Lu Yang (30847)

    Published 2025
    “…</p><p>Conclusions</p><p>The preventive use of PEG-rhG-CSF decreases the incidence of neutropenia in patients undergoing concurrent chemoradiotherapy for NPC, thereby reducing rates of chemotherapy delays and radiotherapy interruptions, with mild adverse reactions that are tolerable by patients.…”
  11. 3231
  12. 3232
  13. 3233

    Measurement of Na<sup>+</sup> ratio in the TE and blastocyst cross-sectional area in the ouabain-treated group. by Ayaka Fujishima (21221913)

    Published 2025
    “…The Na<sup>+</sup> concentration patterns were categorized into two main types: a decrease followed by an increase (Embryo Nos. 1, 3, 7, 9), and no significant change in Na<sup>+</sup> concentration (Embryo Nos. 2, 4, 6, 8). …”
  14. 3234
  15. 3235

    Summary statistics of key variables. by Saul Estrin (8629173)

    Published 2024
    “…We propose that, while there are still agglomeration benefits, the development path followed by cities in developing countries also creates significant agglomeration costs and these act to limit innovation. …”
  16. 3236

    Fig 3 - by Aihong Zheng (20571034)

    Published 2025
    Subjects:
  17. 3237
  18. 3238
  19. 3239
  20. 3240